Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG), highlighting the company's progress with ZUNVEYL in the long-term care market. Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction, as 4Q25 net product revenue reached $2.5 million and FY25 total revenue reached $10.2 million, including $6.8 million of ZUNVEYL sales. More importantly, demand indicators continued to inflect, with bottles dispensed rising 62% quarter-over-quarter to 4,941, with December alone reaching a record 1,859 bottles. Repeat ordering remained strong, supporting management's view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols.
The adoption of ZUNVEYL is becoming durable, as evidenced by the 4Q25 sales of $2.5 million and the 62% quarter-over-quarter increase in bottles dispensed to 4,941, with December reaching 1,859 bottles. Long-term care traction is strengthening with repeat behavior: 729 ordering homes, 82% repeat orders, and 865 prescribers with 69% repeat writers support protocol adoption. This data indicates that ZUNVEYL is gaining acceptance among healthcare providers and facilities, moving from initial trial use to more consistent prescribing patterns.
Alpha Cognition is funded to keep scaling commercialization. The company ended FY25 with $66.0 million in cash, providing a runway into 2027, and expects continued sequential sales growth in 2026. This financial stability allows the company to invest in further market expansion and operational activities. For more details, view the full announcement here.
The updates from Stonegate Capital Partners provide insight into Alpha Cognition's performance and future prospects. The company's focus on long-term care and the positive demand indicators suggest that ZUNVEYL is becoming a more integral part of treatment protocols, which could drive sustained revenue growth. With strong cash reserves and a clear path to continued sales growth, Alpha Cognition appears well-positioned to capitalize on its momentum in the coming years.
